In July 2007, Digene merged with QIAGEN to create one, combined company that will be a market and technology leader in molecular diagnostics.
About QIAGEN
QIAGEN is the leading provider of innovative technologies and products for pre-analytical sample preparation and molecular diagnostic solutions. We have developed a comprehensive portfolio of more than 500 proprietary consumable products and automated solutions for sample collection, nucleic acid and protein handling, separation and purification. We also supply diagnostic kits, tests and assays for human and veterinary molecular diagnostics.
Our products are sold to academic research markets, leading pharmaceutical and biotechnology companies and diagnostic laboratories. QIAGEN also provides purification and testing solutions for applied testing in the fields of forensics, animal and food testing, and pharmaceutical process control.
By merging with Digene, QIAGEN now also develops, manufactures and markets proprietary DNA and RNA tests focused on women's cancers and infectious diseases. The Digene® HPV Test is the only FDA-approved test for the human papillomavirus (HPV), the cause of cervical cancer. Rapidly emerging as a standard of practice in cervical cancer screening, the HPV test aids healthcare professionals in identifying women who are most at risk of having or developing cervical cancer, which today is the world's second-most-common type of cancer affecting women.
QIAGEN employs more than 2,000 people worldwide. Our products are sold through a dedicated sales force and a global network of distributors in more than 40 countries. QIAGEN's customer satisfaction department focuses on continually exceeding our customers' increasing expectations.
Further information about QIAGEN can be found at: www.qiagen.com
|